Amrutanjan Health Care Ltd
Amrutanjan Health Care Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY26 Net Sales: Rs. EBITDA and Operating Margin figures are not explicitly stated in the presentation for the quarter ended 31st March 2026. - Profit (PAT) for Q4 FY26 is Rs.
From Amrutanjan Health Care Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 Net Sales: Rs. 149.77 Cr, up 10.60% YoY (Q4 FY25: Rs. 135.41 Cr)
- Q4 FY26 OTC Products Net Sales: Rs. 132.63 Cr, up 13.13% YoY (Q4 FY25: Rs. 117.24 Cr)
- Q4 FY26 Comfy Net Sales (included in OTC): Rs. 40.79 Cr, up 18.37% YoY (Q4 FY25: Rs. 34.46 Cr; gross sales growth 22%)
- Q4 FY26 Women’s Hygiene & Personal Care Net Sales: Rs. 41.84 Cr, up 21.42% YoY
- Q4 FY26 Beverages Net Sales: Rs. 16.42 Cr, down from Rs. 17.67 Cr YoY
- Q4 FY26 Hydration Drinks Net Sales: Rs. 15.47 Cr (included in Beverages)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New Sanitary Pad plant slated to commence production in May FY27, expected to improve profitability of the Comfy brand. (Page 31)
- No specific capex amounts or other capacity expansions or new plant projects are detailed in the presentation.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q4 FY26 results?
Q4 FY26 Net Sales: Rs. EBITDA and Operating Margin figures are not explicitly stated in the presentation for the quarter ended 31st March 2026. - Profit (PAT) for Q4 FY26 is Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
New Sanitary Pad plant slated to commence production in May FY27, expected to improve profitability of the Comfy brand.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.